RenalGuard System and Contrast Media

Summary

RenalGuard System and Contrast Media is a clinical trial^[1].

Key Facts

• RenalGuard System and Contrast Media is in the country of Italy^[2].
• RenalGuard System and Contrast Media's instance of is recorded as clinical trial^[3].
• RenalGuard System and Contrast Media's start time is recorded as +2009-01-31T00:00:00Z^[4].
• RenalGuard System and Contrast Media's end time is recorded as +2010-12-31T00:00:00Z^[5].
• RenalGuard System and Contrast Media's sponsor is recorded as Clinica Mediterranea^[6].
• RenalGuard System and Contrast Media's number of participants is recorded as {'unit': '1', 'amount': '+292'}^[7].
• RenalGuard System and Contrast Media's title is recorded as Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury^[8].
• RenalGuard System and Contrast Media's short name is recorded as REMEDIALII^[9].
• RenalGuard System and Contrast Media's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• RenalGuard System and Contrast Media's ClinicalTrials.gov ID is recorded as NCT01098032^[11].
• RenalGuard System and Contrast Media's research intervention is recorded as N-acetyl-L-cysteine^[12].
• RenalGuard System and Contrast Media's clinical trial phase is recorded as phase III clinical trial^[13].
• RenalGuard System and Contrast Media's research site is recorded as Clinica Mediterranea^[14].
• RenalGuard System and Contrast Media's research subject recruitment status is recorded as completed^[15].
• RenalGuard System and Contrast Media's study type is recorded as interventional study^[16].